Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?-Reference-Cited by-同舟云学术

Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?

Author:

Bazelier Marloes T.¹,Gallagher Arlene M.¹²,van Staa Tjeerd-Pieter¹²³,Cooper Cyrus³⁴,Leufkens Hubert G. M.¹,Vestergaard Peter⁵,de Vries Frank¹³⁶

Affiliation:

1. Utrecht Institute for Pharmaceutical Sciences; Utrecht University; Utrecht The Netherlands

2. General Practice Research Database; Medicines and Healthcare Products Regulatory Agency; London UK

3. MRC Lifecourse Epidemiology Unit; University of Southampton; Southampton UK

4. NIHR Musculoskeletal Biomedical Research Unit; University of Oxford; Oxford UK

5. The Osteoporosis Clinic; Aarhus University Hospital; Aarhus Denmark

6. Department of Clinical Pharmacy and Toxicology; Maastricht University Medical Centre; Maastricht Netherlands

Funder

GlaxoSmithKline

Novo Nordisk

Top Institute Pharma

Dutch Medicines Evaluation Board

Dutch Ministry of Health

European Calcified Tissue Society

Dutch Organisation of Scientific Research

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

Reference42 articles.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

5. Drugs Causing Bone Loss;Bone Regulators and Osteoporosis Therapy;2019